Kinesin Family Deregulation Coordinated by Bromodomain Protein ANCCA and Histone Methyltransferase MLL for Breast Cancer Cell Growth, Survival, and Tamoxifen Resistance
- 1 April 2014
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 12 (4), 539-549
- https://doi.org/10.1158/1541-7786.mcr-13-0459
Abstract
Kinesins are a superfamily of motor proteins and often deregulated in different cancers. However, the mechanism of their deregulation has been poorly understood. Through examining kinesin gene family expression in estrogen receptor (ER)-positive breast cancer cells, we found that estrogen stimulation of cancer cell proliferation involves a concerted regulation of specific kinesins. Estrogen strongly induces expression of 19 kinesin genes such as Kif4A/4B, Kif5A/5B, Kif10, Kif11, Kif15, Kif18A/18B, Kif20A/20B, Kif21, Kif23, Kif24, Kif25, and KifC1, whereas suppresses the expression of seven others, including Kif1A, Kif1C, Kif7, and KifC3. Interestingly, the bromodomain protein ANCCA/ATAD2, previously shown to be an estrogen-induced chromatin regulator, plays a crucial role in the up- and downregulation of kinesins by estrogen. Its overexpression drives estrogen-independent upregulation of specific kinesins. Mechanistically, ANCCA (AAA nuclear coregulator cancer associated) mediates E2-dependent recruitment of E2F and MLL1 histone methyltransferase at kinesin gene promoters for gene activation–associated H3K4me3 methylation. Importantly, elevated levels of Kif4A, Kif15, Kif20A, and Kif23 correlate with that of ANCCA in the tumors and with poor relapse-free survival of patients with ER-positive breast cancer. Their knockdown strongly impeded proliferation and induced apoptosis of both tamoxifen-sensitive and resistant cancer cells. Together, the study reveals ANCCA as a key mediator of kinesin family deregulation in breast cancer and the crucial role of multiple kinesins in growth and survival of the tumor cells. Implications: These findings support the development of novel inhibitors of cancer-associated kinesins and their regulator ANCCA for effective treatment of cancers including tamoxifen-resistant breast cancers. Mol Cancer Res; 12(4); 539–49. ©2014 AACR.Keywords
Other Versions
This publication has 49 references indexed in Scilit:
- Mediator coordinates PIC assembly with recruitment of CHD1Journal of Bone and Joint Surgery, 2011
- Centriolar Kinesin Kif24 Interacts with CP110 to Remodel Microtubules and Regulate CiliogenesisCell, 2011
- A Rapid, Extensive, and Transient Transcriptional Response to Estrogen Signaling in Breast Cancer CellsCell, 2011
- A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen ResistanceClinical Cancer Research, 2011
- Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancerBritish Journal of Cancer, 2010
- ANCCA/ATAD2 Overexpression Identifies Breast Cancer Patients with Poor Prognosis, Acting to Drive Proliferation and Survival of Triple-Negative Cells through Control of B-Myb and EZH2Cancer Research, 2010
- Chromatin Loading of E2F-MLL Complex by Cancer-Associated Coregulator ANCCA via Reading a Specific Histone MarkMolecular and Cellular Biology, 2010
- Profiling of Estrogen Up- and Down-Regulated Gene Expression in Human Breast Cancer Cells: Insights into Gene Networks and Pathways Underlying Estrogenic Control of Proliferation and Cell PhenotypeEndocrinology, 2003
- Conventional kinesin KIF5B mediates insulin-stimulated GLUT4 movements on microtubulesThe EMBO Journal, 2003
- Role of KIFC3 motor protein in Golgi positioning and integrationThe Journal of cell biology, 2002